Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Aug 11, 2026Locations: 14
Eligibility criteria

Diagnosis of SjD at least 24 weeks prior to Screening Visit and meet the 2016 EU... [+20]

Read more
Status: Not yet recruiting

A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to evaluate safety and tolerability.

Participants needed: 72
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Jul 31, 2026Locations: 1
Eligibility criteria

Age ≥18 to 80 years [+9]

Pregnant or lactating women [+9]

Read more
Status: Not yet recruiting

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.

Participants needed: 90
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Jul 23, 2026Locations: 3
Eligibility criteria

Patients aged ≥ 18 years of age with newly diagnosed, previously untreated AML (... [+7]

Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvemen... [+19]

Read more
Status: Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Participants needed: 24
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Jun 5, 2026Locations: 20
Eligibility criteria

Diagnosis of SLE at least 24 weeks prior to Screening and meet 2019 EULAR / ACR... [+13]

Active inflammatory disease other than SLE. Thyroiditis or secondary Sjogren's s... [+14]

Read more
Status: Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.

Participants needed: 37
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: May 15, 2026Locations: 3
Eligibility criteria

Documented diagnosis of RA which fulfills the 2010 American College of Rheumatol... [+12]

Active inflammatory disease other than RA within 12 months prior to screening or... [+8]

Read more
Status: Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cullinan Therapeutics Inc.Updated: Jan 16, 2026Locations: 11
Eligibility criteria

Aged ≥ 18 years of age. [+9]

Diagnosis of acute promyelocytic leukemia (APL) [+30]

Read more